Welcome to our dedicated page for Regeneron Pharmaceuticals SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of common stock in a series of open-market transactions on March 2, 2026 under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. The shares were sold at volume-weighted average prices ranging from $777.08 to $789.37 per share. After these sales, Ryan directly owned 17,703 Regeneron shares.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported option exercises and related share sales. On February 19, 2026, Zoghbi exercised a non-qualified stock option for 1,638 shares at an exercise price of $0.00, receiving 1,638 shares of common stock at $376.69 per share.
The same day, Zoghbi executed multiple open-market sales totaling 1,638 common shares at prices generally in the high-$770s to around $790 per share, pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025. After these transactions, Zoghbi held 1,703 Regeneron common shares directly.
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 6,308 shares.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades. Reported sale prices ranged from about $775.63 to $787.82 per share.
The filing states these transactions were made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025, which pre-schedules trades. Following the transactions, Ryan directly beneficially owned 17,803 shares of Regeneron common stock.
A person associated with the issuer has filed a Form 144 to potentially sell 400 shares of common stock through J.P. Morgan Securities LLC on or about 02/09/2026 on NASDAQ. The filing lists an aggregate market value of 314204 for these shares and notes that 103902660 shares of this class were outstanding. The 400 shares were originally acquired on 08/22/2013 from the issuer as compensation.
Regeneron Pharmaceuticals security holder plans to sell 2,036 common shares under Rule 144. The planned sale is through UBS Financial Services on NASDAQ, with an aggregate market value of 1,594,534.12 and 103,902,660 common shares stated as outstanding.
The shares to be sold were acquired from the issuer via two transactions: 1,000 shares through a cash exercise of stock options dated 02/09/2026, and 1,036 shares through a restricted stock award dated 12/08/2025.
Regeneron Pharmaceuticals, Inc. filed a Form 13F holdings report disclosing 2 holdings with an aggregate reported market value of $33,799,428. The report is signed by Leonard Brooks, Senior Vice President, Treasurer, and dated 02-06-2026. The filing lists the manager's address as 777 Old Saw Mill River Road, Tarrytown, NY.
Regeneron Pharmaceuticals reports full-year 2025 revenue of $14,342.9M, up slightly from 2024, and net income of $4,504.9M, with diluted EPS of $41.48. Growth is driven by key biologics and extensive collaborations.
Flagship eye drugs EYLEA HD and EYLEA together generated $7,891.0M in 2025 net product sales, while Dupixent global net product sales reached $17,806.7M. Libtayo, Praluent, Kevzara and other products added diversified revenue across immunology, oncology and cardiovascular disease.
The company highlights a broad late-stage pipeline in ophthalmology, immunology, oncology, hematology, neurology and rare diseases, with multiple Phase 3 programs and upcoming regulatory decisions through 2026–2027. Regeneron also underscores its VelociSuite antibody platforms and Regeneron Genetics Center as core innovation engines, supported by major partnerships with Sanofi, Bayer, Alnylam, Intellia and others.
Regeneron Pharmaceuticals, Inc. filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the report.
The company states that the information provided under the results section, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal liabilities and incorporation by reference into other registration statements.